India Pharma Outlook Team | Thursday, 26 June 2025
Hyderabad-based Aurobindo Pharma has made a milestone in its biosimilar growth plans, when its subsidiary CuraTeQ Biologics s.r.o. received clearance by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, a biosimilar of pegylated filgrastim.
Dyrupeg is predominantly approved to avert infections in cancer patients that are being treated with chemotherapy. The third MHRA regulatory approval in one year follows December 2024 approvals of biosimilars Bevqolva and May 2025 approval of Zefylti. The European Commission also approved the product in April 2025, again reinforcing its regulatory capability in target European markets.
This new clearance further solidifies Aurobindo's position in the competitive yet profitable European biosimilar market. With Dyrupeg cleared for UK market launch, Aurobindo is all set to take advantage of the growing trend of demand for cost-containment biologics for the treatment of oncology.
Financially, Aurobindo had consolidated revenues of Rs. 8,382.1 crore for March quarter 2025, increasing year-on-year by 11 percent driven primarily by revenues from overseas markets. The US market registered an increase of 13.5 percent in formulation revenue and Europe registered a strong 17.2 percent increase.
Also Read: The Evolution of In-Vitro Diagnostics: Trends and Future Prospects
While the company posted a top-line growth, the company posted a marginal drop in net profit to Rs. 902.8 crore from Rs. 907.4 crore in the previous year. EBITDA grew 7.1 percent to Rs. 1,792 crore, with the margin at 21.38 percent.
Where Aurobindo's finances have been erratic, its sustained push forward in high-value biosimilars has proven to be a strong bulwark against price erosion in the legacy generics space as well as a strong support pillar for future growth.
, CDSCO.jpg)
